Klotho Neurosciences Stock (NASDAQ:KLTO)

Financials Chart

Previous Close

$0.18

52W Range

$0.11 - $13.10

50D Avg

$0.28

200D Avg

$0.64

Market Cap

$4.68M

Avg Vol (3M)

$324.12K

Beta

-0.02

Div Yield

-

KLTO Company Profile

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

-

Website

KLTO Performance

KLTO Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-5.54M	$-631.32K	$-574.37K
Net Income	$-6.15M	$-707.46K	$-598.59K
EBITDA	$-5.79M	$-631.24K	$-574.23K
Basic EPS	-	-	-
Diluted EPS	-	-	-

Fiscal year ends in Dec 24 | Currency in USD